GEN Exclusives

More »

Best Science Apps

More »
Dec 01, 2013 (Vol. 33, No. 21)

Optogenetics Pro

URL:bit.ly/1bKUi9m
  • Includes many parameters, pro version includes complete brain atlas
  • Methods for generating plots not given
Platform: iPad/iPhone  
Cost: $1.99

Optogenetics is a recently developed (and commonly employed) experimental tool in neuroscience research that allows researchers to either activate or inhibit populations of cells through the delivery of light to those cells. Of course, the efficiency with which one can activate/inhibit the target cells depends on a number of factors related to the delivery of light, such as the diameter of the optical fiber and the power of the light being applied. The success of the procedure also depends on which light-activatable proteins are being employed and which region of the brain is being targeted. Using the Optogenetics Pro app (and to a more limited extent, the free version of the app), researchers can explore the relationship between the aforementioned experimental parameters and the resulting penetration depth of illumination. Users specify the various parameters listed above, and the app generates a plot of optical power at the fiber tip versus the penetration depth of illumination. This can facilitate the design and implementation of optogenetics experiments.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?